Trystram N, Abitbol V, Tannoury J, Lecomte M, et al. Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study. Aliment Pharmacol Ther 2021 Mar 1. doi: 10.1111/apt.16312.
PMID: 33647174